glp-1 news today oct 2 2025 What's next for innovation: A primer on the race reshaping pharma and chronic disease care Who Gets the Shot? GLP-1

Buyers who understand that distinction will be able to evaluate LeviaPatch fairly against what supplement-category support can realistically accomplish

Novo Nordisk is the market leader: Ozempic (weekly injection for type 2 diabetes) Wegovy (higher-dose weekly injection for obesity) Rybelsus ( Oral tablets for diabetes Oral tablets for weight management is in phase 3 trials) Eli Lilly is the other major player: Mounjaro (weekly injection for type 2 diabetes) Zepbound (higherdose weekly injection for obesity) This duopoly meant that both stocks had an incredible run-up from 2020 to 2024

M., Cozine, E

Let's dive in